Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| Overall, I'm enthusiastic with our record-breaking revenue performance in 2023 |
| Based on this, we feel we are poised for continued growth and market expansion |
| Our solid results reflect continued improvements in consistency of returns from our scalable commercial strategy in addition to the early contributions of our Indego product lines that we acquired in late 2022 |
| Looking forward, we're optimistic about our 2024 business outlook and are excited as we build up the momentum generated -- as we build upon the momentum that was generated in 2023 |
| First, we've bolstered our operating leverage, reflecting a more efficient and scalable operational model |
| Our clinically proven patient improvements in functional outcomes support our efforts to elevate the standard of care for neuro rehabilitation |
| 36% growth year-over-year in the fourth quarter is really something to be proud of |
| The output from our commercial team led to a record year of EksoHealth devices sold |
| For our EksoHealth business, our go-to-market strategy enabled us to drive more multiunit orders from network operators that helped us achieve our strong revenue growth and improve our operating leverage |
| We believe we are well positioned to build upon this momentum to drive sustained growth for our EksoHealth enterprise devices as we continue to strengthen our distribution network and expand our pipeline of opportunities |
| Overall, 2023 was a momentous year for Ekso Bionics highlighted by record revenue growth |
| And again, generally speaking, we have had a very positive reaction by our health community regarding this program |
| We believe GaitCoach will reduce training demands and increase utilization, making the device more intuitive and easier to use for both patients and physical therapists and marking a milestone in improvement of our product portfolio |
| We're focused on building out the market across the continuum of care for our pioneering EksoHealth devices and believe we are well positioned to deliver on our objectives |
| We believe that consolidating our teams onto a single system will improve collaboration across our sites and once fully implemented, will reduce audit and compliance costs |
| We're excited to have closed out 2023 on a positive note, highlighted by record annual revenues of $18.3 million, an increase of 42% from the prior year period |
| Additionally, the economic value proposition for neuro rehab providers to implement our EksoNR and Ekso Indego therapy devices into their programs have been shown to increase patient throughput and drive higher patient volumes |
| On the international front, we achieved solid performance across EMEA and APAC regions as we generated an increase in sales volume built on the strength of our distribution network |
| Not only are we getting more placements, but our network enables us to gain operating leverage abroad |
| One of the things that we've been hard at work on is building a strong pipeline and a scalable go-to-market strategy inside of our organization |
| By reducing supply constraints and substantially lowering costs through our contract manufacturer relationship, we believe we'll be able to better meet the supply and pricing demands of a potentially high-volume industrial customer pipeline |
| Ekso has spent a decade building strong relationships with our health care provider network that's out there |
| Ekso is committed to delivering well-built affordable products and to help enable this potentially life-changing technology reach a higher number of individuals living with a spinal cord injury |
| So between the geographic expansion, the scalable go-to-market strategies and the work with the integrated delivery networks, we are seeing this growth and we believe that this growth will continue going forward |
| We did a lot of work on this in 2023, and we really saw the positive effects of that in the back half of the year |
| While revenue contributions from our industrial segment have recently been at modest levels, we remain steadfast in our commitment to maximize EVO's placement in large industrial settings, leveraging a significant emerging market opportunity |
| We believe there is still room to improve on inventory efficiency |
| In 2023, we drove notable progress in our industrial product line, especially on the operational side with the implementation and initial supply of EVOs from our new high-volume contract manufacturer |
| I'm pleased to report several key achievements and developments within Ekso's operations in 2023 |
| We believe this is indicative of the operating leverage we're able to achieve going forward as we continue to manage expenses |
| Statement |
|---|
| Net loss applicable to common stockholders for the fourth quarter was $3.2 million or $0.22 per basic and diluted share compared to a net loss of $3.2 million or $0.24 per basic and diluted share for the same period of 2022 |
Please consider a small donation if you think this website provides you with relevant information